QualiCell® Human Amniotic Fluid Stem Cells

Comparison of AFSC-exos and HBM-exos for the Treatment of NEC

Neonatal necrotizing enterocolitis (NEC) is a devastating condition for newborns. While exosomes derived from human amniotic fluid stem cells (AFSC) and human breast milk (HBM) are known to offer protection, the specific mechanisms behind their efficacy remain unclear. Hu's team aims to compare the therapeutic effects of AFSC-derived and HBM-derived exosomes in a NEC mouse model and to identify their respective regulatory pathways in alleviating intestinal injury and inflammation.

While both AFSC-exos and HBM-exos are known to benefit NEC models, their specific molecular mechanisms remain unclear. To investigate, they established a NEC mouse model (Fig. 1A) and administered isolated exosomes. The NEC group exhibited significant intestinal injury, particularly in the ileum. Intervention with both AFSC-exos and HBM-exos effectively alleviated injury and lowered NEC scores (Fig. 1B, C). Notably, HBM-exos were more effective at restoring ileal crypt numbers than AFSC-exos (Fig. 1D, E). Furthermore, both exosome types successfully rescued the depletion of Lgr5⁺ intestinal stem cells and Lgr5 gene expression levels caused by NEC (Fig. 1F-H). While these treatments reduced intestinal severity, they did not significantly alter overall body weight or survival during this short-term intervention These results suggest that while both exosome sources are therapeutic, they likely operate through distinct mechanisms.